View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 21, 2022

Valneva receives up to £20m vaccine R&D funding in Scotland

The funding will be received in two separate grants, to support the manufacture of Valneva’s Covid-19 jab and other vaccines.

By Darcy Jimenez

The Scottish subsidiary of vaccine maker Valneva has been awarded up to £20m funding for the research and development of vaccines including its Covid-19 jab.

The investment from Scotland’s national economic development agency, Scottish Enterprise, is comprised of two separate grants that will be provided over the next three years, starting from March 2022.

The first grant of up to £12.5m will support R&D related to the manufacture of the French company’s Covid-19 vaccine candidate, VLA2001. The second payment of up to £7.5m will go towards the manufacturing processes for Valneva’s other vaccines.

Scottish Government business minister Ivan McKee said: “Valneva is a valued contributor to our life sciences sector and the Livingston facility is an important asset, developing and manufacturing vaccines for the prevention and treatment of several infectious diseases.

“This funding package will support high quality jobs, drive further research and underpin the company’s operations in Scotland.”

Valneva has recently published updates on several its vaccine candidates. In January, the company announced that three doses of its Covid-19 jab successfully neutralised the Omicron variant of SARS-CoV-2 in a Phase I/II trial.

Valneva is also developing a Lyme disease vaccine in partnership with Pfizer, and reported positive Phase II data on the candidate earlier this month. The companies plan to evaluate a three-dose vaccination schedule of the jab, known as VLA15, in an upcoming Phase III trial.

Valneva’s single-shot jab for the mosquito-borne viral infection chikungunya, VLA1553, generated neutralising antibody titres in 98.5% of participants in Phase III studies last year. A Phase III trial of VLA1553 in adolescents was initiated in January. The vaccine maker intends for the shot to be produced at its Livingstone, Scotland facility.

Commenting on the Scottish Enterprise grant, Valneva CEO Thomas Lingelbach said: “From the only inactivated, whole virus Covid-19 vaccine candidate in clinical development in Europe, to the most clinically advanced vaccine candidate against chikungunya in the world, Scottish Enterprise’s investment will support progress across Valneva’s research and development portfolio – as well as jobs and growth in Scotland.”

A Valvena spokesperson also told Pharmaceutical Technology the funding will “enable the operationalisation” of a new, state-of-the-art manufacturing plant that was built to complement the company’s existing Livingstone facility.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU